Quantum BioPharma Ltd. (NASDAQ: QNTM) has received U.S. Food and Drug Administration clearance to launch a Phase 2 clinical trial of Lucid-MS, a patented, first-in-class drug candidate for multiple sclerosis. The milestone, highlighted in a recent BioMedWire editorial, positions the company to test a novel mechanism of action that aims to protect and potentially rebuild the myelin sheath rather than suppress the immune system. If successful, the trial would mark the first time a drug based on this approach is tested in people living with MS. To view the full press release, visit https://ibn.fm/whtAF.
Current MS treatments primarily focus on modulating or suppressing the immune system to reduce relapses and slow disability progression. However, they do not directly repair or protect myelin, the protective coating around nerve fibers that is progressively damaged in MS. Lucid-MS, developed by Quantum’s wholly owned subsidiary Lucid Psycheceuticals Inc., has demonstrated in preclinical models the ability to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis. This regenerative potential could offer a complementary or alternative strategy for patients who do not respond adequately to existing therapies.
The FDA’s clearance to proceed with a Phase 2 trial represents a critical validation of Quantum’s research and development efforts. Phase 2 trials are designed to evaluate both safety and efficacy in patients, and a successful outcome could pave the way for larger Phase 3 studies and eventual regulatory approval. For Quantum BioPharma, a biopharmaceutical company focused on neurodegenerative and metabolic disorders, this milestone could significantly enhance its pipeline and attract further investment. The company’s newsroom, available at https://ibn.fm/QNTM, provides ongoing updates on QNTM.
Beyond Lucid-MS, Quantum BioPharma holds a diverse portfolio. It invented UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses. For more information about Unbuzzd, visit www.unbuzzd.com.
The BioMedWire editorial underscores the potential of Lucid-MS to address a significant unmet need in MS treatment. By targeting myelin protection and repair, Quantum BioPharma is pursuing a fundamentally different approach that could complement or even replace immune-suppressing therapies. The Phase 2 trial will be closely watched by clinicians, investors, and patients alike, as its results could reshape the treatment landscape for multiple sclerosis. For more information about InvestorWire, visit https://www.InvestorWire.com.
